Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment:A case report

lNTRODUCTlON

Renal cell carcinoma (RCC) derives from malignant tumours originating in the renal parenchymal urotubular epithelium. Although it only accounts for approximately 2% of all malignant tumours, its morbidity and mortality rates are increasing annually[1,2]. Clear cell RCC (ccRCC) is the most common subtype of RCC, accounting for 80% of all cases[3]. Although surgical excision can cure localised RCC,recurrence is common. In addition, many RCC patients do not present clinical symptoms until they have developed unresectable, locally progressive, or metastatic lesions. Consequently, many patients miss the window for surgery. Moreover, RCC is unresponsive to standard radiotherapy and chemotherapy, and its incidence and mortality rates are increasing with each passing year. Thus, targeted therapy is the most effective treatment for ccRCC patients. Currently, the main targeted drugs for ccRCC include sorafenib, sunitinib, pazopanib, and cabozantinib; all of which achieve anti-tumour effects by impacting vascular endothelial growth factor receptor (VEGFR) expression and inhibiting blood pressure angiogenesis and cell proliferation[2,4].

Apatinib (Hengrui Pharmaceutical Co, Ltd, Shanghai, China) is a highly selective inhibitor of VEGFR-2 tyrosine kinase. In December 2014, it became the first China Food and Drug Administration approved anti-angiogenic therapy for treating metastatic gastric cancer. Its official approved use was as a thirdline or later treatment[5]. It acts to specifically inhibit the VEGFR tyrosine kinase activity, thereby inhibiting tumour angiogenesis. Since its approval, given its effectiveness in treating gastric cancer, it has also been used to treat other tumours. Hence, apatinib has shown to be a strikingly effective new option against multifarious malignancies, including advanced non-small cell lung cancer, metastatic triple-negative breast cancer, angiosarcoma, desmoplastic small round cell tumour, advanced intrahepatic cholangiocarcinoma, and myxoid/round cell liposarcoma[6-10].

It is also important to note that since their earthly father has abandoned them, the Grimms have the children turn to God the Father to save them (Zipes 1997). Return to place in story.

However, to the best of our knowledge, cases have yet to be reported regarding apatinib’s usefulness in both the treatment of RCC and controlling tumour growth. Thus, in the current report, we present an advanced ccRCC case with multiple metastases (Stage IV) in a 48-year-old male with an extremely poor general status (Karnofsky 30%).

CASE PRESENTATlON

Chief complaints

In March 2010, a middle-aged (48-year-old) man was admitted to Dongyang Hospital Affiliated to Wenzhou Medical University complaining of soreness and swelling on his waist and back.

History of present illness

The patient’s symptoms of persistent pain had started one year prior. However, two weeks before admission, it had worsened to the point that he could not lie down on his back at night. Oral analgesics did not control his pain, which he reported suffering from in frequent bouts.

Blood tests showed increased leukocytes and tumour markers. The neutrophil, hemoglobin, platelets and biochemistry was normal.

History of past illness

In my dual1 profession as an educator and health care provider, I have worked with numerous children infected with the virus that causes AIDS. The relationships that I have had with these special kids have been gifts in my life. They have taught me so many things, but I have especially learned that great courage can be found in the smallest of packages. Let me tell you about Tyler.

In May 2017, the patient was admitted to the Fourth Affiliated Hospital of Zhejiang University’s Medical College. Urinary system and bladder ultrasounds showed the presence of a parenchymal spaceoccupying tumour of the left kidney. Chest and abdomen computed tomography (CT) scans suggested that the tumour had triggered implantation metastasis at multiple sites, including parapyloric nodules,lumbar areas, multiple nodules in both lungs, left pleura, left breast, and the abdominal wall. Realising the seriousness of his condition, the patient immediately visited the Cancer Hospital affiliated with Fudan University, where he was advised to undergo a left nephrectomy, followed by adjuvant therapy.However, the patient was resistant and refused the suggested treatment. Instead, he consumed traditional Chinese medicine orally at home. Unfortunately, by March 2018, the tumours had progressed and the mass on his back had grown more.

Personal and family history

The patient had no history of smoking or drinking alcohol. There was no relevant family history.

Physical examination

The patient’s vital signs were stable in March 2018. However, the clinical examination showed tenderness in the lower back and localised skin swelling.

Laboratory examinations

The North Wind woke her betimes next morning, and puffed19 himself up, and made himself so big and so strong that it was frightful20 to see him, and away they went, high up through the air, as if they would not stop until they had reached the very end of the world

Imaging examinations

Lumbar CT scans, taken on March 5, 2018, showed that the patient’s lumbar spinous process level space had been blocked by the deterioration and absorption of lumbar 2 appendages and the invasion of the spinal canal (Figure 1).

You have come just in time, said the Prince, for I should have been married to-morrow; but I will not have the long-nosed Princess, and you alone can save me

Further diagnostic work-up

Considering the medical history and follow-up treatments in this case, a puncture biopsy of the mass was recommended. Thus, on March 17, 2018, a puncture biopsy was performed on the back tumour,with guided colour Doppler ultrasound. The observed malignant tumours were consistent with ccRCC according to their morphology and histology; CK+, CK7-, CK20-, cam5.2+, CD10+, EMA+, 34beta E12-, Ki-67+ (10%) (Figure 2).

MULTlDlSClPLlNARY EXPERT CONSULTATlON

This patient had a clear diagnosis of ccRCC with multiple metastases (Stage IV; IMDC mid-risk). Given the multiple metastases, surgery was not advisable. Instead, medical treatment was considered.

FlNAL DlAGNOSlS

The patient was diagnosed with ccRCC with multiple metastases (Stage IV; IMDC mid-risk) in various organs, including the lungs (contralateral), bones, pleura, abdominal cavities, and lymph nodes. The patient had an extremely poor general status (Karnofsky 30%) and was informed on his poor prognosis.

TREATMENT

Informed written consent was obtained from the patient for publication of this report and any accompanying images.

OUTCOME AND FOLLOW-UP

In response to apatinib treatment, the lump in his back shrank after one week. The patient was thus able to lie down, and his pain in so doing was alleviated. He was able to move freely and his performance status improved drastically (Karnofsky 90%). CT taken on July 26, 2018, revealed left inferior pole RCC(diameter:4.5 cm), L2 spinous process metastatic bone tumours secondary to corresponding plane spinal stenosis, and multiple metastatic tumours in both the lungs (both the length and diameter of the lesion were approximately 1.0 cm), and he had a stable disease (SD), according to the RECIST 1.1 criteria(Figure 3). After several months, a follow-up CT taken on October 20, 2018, and compared with the prior scan (July 26, 2018), suggested that the left inferior pole RCC had reduced in size (diameter:3.9 cm).Moreover, the rest of the metastatic tumours did not demonstrate any noticeable change (in terms of growth) (Figure 3). Furthermore, the patient showed a SD, according to the RECIST 1.1 criteria. The follow-up CT taken on March 5, 2019 showed that the left inferior pole RCC had enlarged (diameter:Approximately 4.7 cm). However, the progression was slow, according to the RECIST 1.1 criteria(Figure 3). During this period, combination immunotherapy was recommended due to the increase in tumour size. However, the patient rejected it for economic reasons. Thereafter, he was followed up with several times and was reported to be stable till December 2020. The follow-up CT, taken on December 14, 2020, showed that the left inferior pole RCC had increased in size (diameter:Approximately 5.5 cm).Considered together with the other lesions, this indicated that the disease had resumed progression(Figure 3). Strikingly, until this point, the patient had experienced 32 mo of progression-free survival(PFS).

And you, she turned to George, you are making your home in this country? You do not intend to return to England just yet? ！ ， 。， ， ？？ She seemed relieved when she heard that George had bought a farm near our own farm and intended to settle in South Africa

DlSCUSSlON

RCC is considered a serious disease worldwide because of the extent to which it endangers human life and health. It demonstrates insidious onset, low survival rate, and high morbidity and mortality. RCC is the second most common urinary tumour, accounting for 2%–3% of all adult malignant tumours[2].Currently, the best treatment for RCC is surgical resection. In 2010, radical nephrectomy was proposed as a viable option for advanced RCC patients in sufficiently good general condition such that they could tolerate surgery[11]. However, approximately one third of RCC patients demonstrate distant metastasis at the time of initial diagnosis. Thus, they have missed the window for surgery. Statistically, RCC patients showing a 2-year survival rate amount to less than 20% of all cases, whereas the 5-year survival rate is approximately 10%[2]. Therefore, pursuit of medical treatment for RCC is also extremely important. Luckily, over the past decade, a range of therapeutic options have been approved for mRCC,including the targeted, immune checkpoint, and combined immune checkpoint treatments[12]. In the mid to late 2000s, targeted therapies, including inhibitors of VEGF and the mammalian target of rapamycin pathway have entered into the clinical toolkit, thus expanding the range of standard ccRCC therapy options[13]. Consequently, the 5-year survival rate for advanced RCC has increased to nearly 20%[2]. Recent studies have shown that immunotherapy and target therapy combined with immunotherapy have led to positive results in the PFS of advanced RCC patients[14,15].

In conclusion, this case report indicates that apatinib significantly augmented the quality of life for an RCC patient. It also markedly improved his PFS. Thus, apatinib, like other multi-target drugs, may be useful as a first-line therapeutic drug for advanced RCC. It may be a particularly helpful curative option when patients are found to be intolerant of other targeted drugs.

Apatinib is an orally bioavailable small-molecule VEGFR2 tyrosine kinase inhibitor. It inhibits VEGFmediated endothelial cell migration and proliferation, thereby arresting angiogenesis in tumours[22]. In addition, this agent mildly inhibits c-Kit and c-Src tyrosine kinases. Studies have shown that apatinib can arrest the growth of tumour cells in advanced gastric cancer patients. It has been shown to similarly affect advanced epithelial ovarian cancer, recurrent malignant glioma, and metastatic breast cancer[5,6,8,23,24].

Now there was no one left in the house but the innkeeper s daughter. She meant well and had not taken part in their godless deeds. She opened all the doors for the stranger and showed him piles of treasure. However, the prince said that she should keep everything. He wanted none of it, and with his servant he rode on his way.

However, this study has some limitations. Because case reports cannot replace randomised controlled trials, it is unclear whether apatinib is suitable for all RCC patients. Further prospective studies are required to optimise the use of apatinib in the treatment of RCC and identify patients that can benefit from this agent.

CONCLUSlON

Researchers have shown that targeted therapies, such as bevacizumab, sunitinib, and axitinib, have a 25%–35% overall response rate among treatment-naive patients, a disease control rate of 45%–80%, and a median PFS ranging from 6.5–11 mo[16]. Currently, immunotherapy has also been used as a first-line treatment[17]. The median PFS for advanced first-line RCC immunotherapy is between 11.2 and 15.1 mo[18-20]. However, immunotherapy, being very expensive and not yet insured, is not an economic firstline RCC treatment[21].

In the present case, the patient was diagnosed with ccRCC with multiple metastases (Stage IV) and was in deplorable physical condition. Therefore, targeted therapy was recommended. Given the patient’s intolerance to pazopanib and our uncertainty with regards to his response to sunitinib, we chose apatinib as this drug had been reported to be successful in treating various malignancies. The patient showed a positive clinical response to apatinib. His general status improved drastically, and nearly 32 mo of PFS was realised, which was longer than any previously reported case. Although, the patient showed a slow disease progression, apatinib was still effective in reversing disease severity.Thus, we posit an ideal treatment combination of apatinib and immunotherapy. Unfortunately, the patient did not receive immunotherapy concurrently for financial reasons.

Hu ZL and Wei HP were medical oncologist of the patients, who consulted the literature and participated in the drafting of the manuscript; Mao J was responsible for the imaging data of patients; all authors have approved the final version of the manuscript to be submitted.

One afternoon I rushed home overjoyed. I won a prize, Mamma, I signed. I earned a gold key for my university work; Phi Beta Kappa. I spelled each Greek letter for her.

Initially, the patient was administered pazopanib targeted treatment. However, two weeks later he experienced severe adverse reactions in the form of grade IV oral mucositis. Considering his intolerance to pazopanib, we attempted targeted treatment with apatinib, at a dose of 250 mg daily since April 2018.There were no grade III or higher adverse reactions during apatinib treatment.

27. A beautiful son: A first born son would be the crown prince. Giving up the crown prince to the manikin would not be just a personal tragedy for the Queen, but a possible disaster for her kingdom which relies on progeny to avoid strife in the royal lineage.Return to place in story.

The authors declare that they have no conflict of interest.

I took Gul back to my palace, and from that time till now I have treated her as a dog is treated, and I have cared for my dog as though it were my wife

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See:https://creativecommons.org/Licenses/by-nc/4.0/

China

Hang-Ping Wei 0000-0002-2904-7086; Jie Mao 0000-0002-6723-072X; Zhu-Liang Hu 0000-0002-9032-6471.

Fan JR

A

Fan JR